Kennislacunes

Knowledge gaps

Some patients with IBM deteriorate more rapidly than others. As yet it is not known whether patients with rapid progression and patients with slow progression differ with respect to treatment response. Therefore, the indication and effectiveness of (types of) immunomodulatory and immunosuppressive drugs remains unknown.

1. Which patients with IBM could benefit from immunomodulatory and immunosuppressive drugs?
2. What is the effect of different immunomodulatory and immunosuppressive drugs in patients with IBM?